Loading...

FITC anti-mouse CD4 Antibody

Pricing & Availability
Clone
RM4-5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
RM4-5
C57BL/6 mouse splenocytes stained with CD4 (clone RM4-5) FITC (solid line) or rat IgG2a, κ FITC isotype control (dotted line).
  • RM4-5
    C57BL/6 mouse splenocytes stained with CD4 (clone RM4-5) FITC (solid line) or rat IgG2a, κ FITC isotype control (dotted line).
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
100509 50 µg £21
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100510 500 µg £68
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes and a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a co-receptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
BALB/c mouse thymocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

The RM4-5 antibody blocks the binding of GK1.5 antibody and H129.19 antibody to CD4+ T cells, but not RM4-4 antibody. Additional reported applications (for the relevant formats) include: blocking of ligand binding, in vivo depletion of CD4+ cells1, and immunohistochemistry of acetone-fixed frozen tissue sections2,3,11 and paraffin-embedded sections11. Clone RM4-5 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. Instead, acetone frozen or zinc-fixed paraffin sections are recommended. The Ultra-LEAF™ Purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100575 and 100576).

Application References

(PubMed link indicates BioLegend citation)
  1. Kruisbeek AM. 1991. In Curr. Protocols Immunol. pp. 4.1.1-4.1.5. (Block, Deplete)
  2. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  3. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045.
  4. Muraille E, et al. 2003. Infect. Immun. 71:2704. (IHC)
  5. León-Ponte M, et al. 2007. Blood 109:3139. (FC)
  6. Bourdeau A, et al. 2007. Blood doi:10.1182/blood-2006-08-044370. (FC)
  7. Matsumoto M, et al. 2007.J. Immunol.178:2499. PubMed
  8. Shigeta A, et al. 2008. Blood 112:4915. PubMed
  9. Zaborsky N, et al. 2010. J. Immunol. 184:725. PubMed
  10. Rodrigues-Manzanet R, et al. 2010. P. Natl Acad Sci USA 107:8706. PubMed
  11. Whiteland JL, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)
Product Citations
  1. Yu HH, et al. 2021. J Am Heart Assoc. 10:e023077. PubMed
  2. Stone VM, et al. 2022. iScience. 25:105070. PubMed
  3. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  4. Xu C, et al. 2017. Biochemical and Biophysical Research Communications. 10.1016/j.bbrc.2017.05.071. PubMed
  5. Wang L, et al. 2018. Exp Ther Med. 15:1532. PubMed
  6. Zhou J, et al. 2019. Immunity. 50:403. PubMed
  7. Fachi JL et al. 2019. Cell reports. 27(3):750-761 . PubMed
  8. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 5:64. PubMed
  9. Yang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  10. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  11. Li ZX, et al. 2022. Arch Virol. :. PubMed
  12. Zhang S, et al. 2022. Cell Death Dis. 13:844. PubMed
  13. Abou-Hamad J, et al. 2022. iScience. 25:105524. PubMed
  14. Moodley D, et al. 2016. Proc Natl Acad Sci U S A. 113: 9852 - 9857. PubMed
  15. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  16. Christian LS, et al. 2021. Cell Reports. 35(6):109118. PubMed
  17. Kagoya Y, et al. 2018. Nat Commun. 9:1915. PubMed
  18. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  19. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  20. Gilleron J et al. 2018. Cell reports. 25(12):3329-3341 . PubMed
  21. Achmus L, et al. 2020. Front Neurol. 11:577971. PubMed
  22. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  23. Zheng H, et al. 2021. Frontiers in Cell and Developmental Biology. 9:641527. PubMed
  24. Yang W, et al. 2020. Nat Commun. 3.553472222. PubMed
  25. Lin H, et al. 2020. Front Microbiol. 1.330555556. PubMed
  26. Ogawa M, et al. 2019. J Biol Methods. 5:e102. PubMed
  27. Sehnert B, et al. 2022. Front Immunol. 13:921488. PubMed
  28. Yang W, et al. 2020. Mucosal Immunol. 13:788. PubMed
  29. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  30. Zhao B, et al. 2021. Cell Reports. 36(3):109401. PubMed
  31. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  32. Jin X, et al. 2019. Mol Cell. 73:22:00. PubMed
  33. Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed
  34. Zhang C, et al. 2021. Clin Transl Immunology. 10:e1310. PubMed
  35. Wang C, et al. 2021. Cell Rep. 37:110021. PubMed
  36. Forni MF, et al. 2021. Front Oncol. 11:667715. PubMed
  37. Yi M, et al. 2021. J Hematol Oncol. 14:27. PubMed
  38. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  39. Wang Z, et al. 2021. J Virol. 95:e0141421. PubMed
  40. Sundberg T, et al. 2014. Proc Natl Acad Sci U S A. 111:12468. PubMed
  41. Wiesner D, et al. 2015. PLoS Pathog. 11:1004701. PubMed
  42. Graham DB, et al. 2018. Nat Med. 24:1762. PubMed
  43. Terashima Y, et al. 2020. Nat Commun. 11:609. PubMed
  44. Zhang L, et al. 2021. Methods Mol Biol. 2388:175. PubMed
  45. Gu Y, et al. 2021. Cell Res. Online ahead of print. PubMed
  46. Qi X, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.25. PubMed
  47. Deng Z, et al. 2017. Oncogene. 36:639. PubMed
  48. Jackstadt R, et al. 2019. Cancer Cell. 36:319. PubMed
  49. Duan RN, et al. 2021. J Neuroinflammation. 18:145. PubMed
  50. Repáraz D, et al. 2022. J Immunother Cancer. 10:. PubMed
  51. Spinner C, et al. 2015. Sci Rep. 5:16269. PubMed
  52. Mencarelli A, et al. 2016. Sci Rep. 6:30802. PubMed
  53. Gozgit JM, et al. 2021. Cancer Cell. :. PubMed
  54. Srivastava S, et al. 2019. Cancer Cell. 35:489. PubMed
  55. Liao T, et al. 2017. Front Immunol. 8:1334. PubMed
  56. Fang E, et al. 2022. MedComm (2020). 3:e117. PubMed
  57. Belgiovine C, et al. 2021. Eur J Immunol. 51:2677. PubMed
  58. Takeshita Y, et al. 2021. Neurol Neuroimmunol Neuroinflamm. 8:. PubMed
  59. Kulkarni R, et al. 2021. PLoS One. 16:e0257191. PubMed
  60. Zhang YN, et al. 2020. EBioMedicine. 56:102819. PubMed
  61. Sebastian M, et al. 2016. J Immunol. 196: 144 - 155. PubMed
  62. Wan X, et al. 2018. Nature. 560:107. PubMed
  63. Wheeler MA, et al. 2019. Cell. 176:581. PubMed
  64. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  65. Su X, et al. 2022. J Transl Med. 20:378. PubMed
  66. Anger-Góra N, et al. 2021. Oncol Lett. 22:582. PubMed
  67. Lischke T, et al. 2013. Infect Immun . 81:4091. PubMed
  68. Alhosaini K, et al. 2021. Brain Sci. :11. PubMed
  69. Lü X, et al. 2021. Exp Ther Med. 22:1005. PubMed
  70. Puigdelloses M, et al. 2021. J Immunother Cancer. 9:. PubMed
  71. Aguilera M, et al. 2021. Int J Mol Sci. 22:. PubMed
  72. Li Y, et al. 2021. Cell Death Dis. 12:1001. PubMed
  73. Yi W, et al. 2021. Cell Reports. 34(13):108922. PubMed
  74. Chou T, et al. 2016. Nat Commun. 7:11904. PubMed
  75. Kyburz A, et al. 2019. J Allergy Clin Immunol. 143:1496. PubMed
  76. Shiozawa S, et al. 2022. iScience. 25:103537. PubMed
  77. Chen C, et al. 2021. J Virol. 95:e0082921. PubMed
  78. Tu J, et al. 2022. Mol Ther Nucleic Acids. 27:733. PubMed
  79. Kyburz A, et al. 2017. Clin Exp Allergy. 47:1331. PubMed
  80. Dong M, et al. 2022. J Immunother Cancer. 10:. PubMed
  81. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  82. Stephens WZ, et al. 2021. Cell Rep. 37:109916. PubMed
  83. Zhou X, et al. 2021. Cell Reports. 34(1):108601. PubMed
  84. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  85. Takenori Inomata, Jing Hua, Antonio Di Zazzo 2016. Sci Rep. 6:39924. PubMed
  86. Kim M, et al. 2018. Immunity. 49:151. PubMed
  87. Papa I, et al. 2017. Nature. 547:318. PubMed
  88. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  89. Zhang J, et al. 2018. Nature. 553:91. PubMed
  90. Unsinger J, et al. 2021. J Leukoc Biol. 109:697. PubMed
  91. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  92. Richardson ET, et al. 2015. PLoS One. 10: 1371. PubMed
  93. Uribe-Herranz M, et al. 2018. JCI Insight. 3. PubMed
  94. Bell CR, et al. 2022. Nat Commun. 13:2063. PubMed
  95. de Assis LVM, et al. 2022. Commun Biol. 5:461. PubMed
  96. Bao Z, et al. 2020. Ann Transplant. 25:e921287. PubMed
  97. Cantor DJ et al. 2019. Cell reports. 26(1):108-118 . PubMed
  98. Lu J, et al. 2022. Int J Mol Med. 49:. PubMed
  99. Harrison DK, et al. 2021. Transplantation. 105:540. PubMed
  100. Zegarra‐Ruiz DF et al. 2018. Cell host & microbe. 25(1):113-127 . PubMed
  101. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 0.252777778. PubMed
  102. Wang X, et al. 2022. Elife. 11:. PubMed
  103. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  104. Baptista M, et al. 2016. Nat Commun. 7:12175. PubMed
  105. Leon-Ponte M, et al. 2006. Blood. 109:3139. PubMed
  106. Burton OT, et al. 2018. Clin Exp Allergy. 48:288. PubMed
  107. Yeon S, et al. 2017. Sci Rep. 10.1038/s41598-017-11492-7. PubMed
  108. Helfricht A, et al. 2020. J Exp Med. 217:00:00. PubMed
  109. Ren D, et al. 2020. Am J Cancer Res. 2851:10. PubMed
  110. Wheeler MA, et al. 2020. Nature. 578:593. PubMed
  111. Krotova K, et al. 2019. Mol Ther Oncolytics. 15:166. PubMed
  112. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
  113. Ren X, et al. 2021. Cell Death Dis. 12:484. PubMed
  114. Rana MN, et al. 2021. Front Pharmacol. 12:643215. PubMed
  115. Chow AK, et al. 2021. Cellular and Molecular Gastroenterology and Hepatology. :. PubMed
  116. Gonzalez-Figueroa P, et al. 2021. Cell. 184(7):1775-1789.e19. PubMed
  117. Tripathi D, et al. 2016. Nat Commun. 7:13896. PubMed
  118. Campisi L, et al. 2016. Nat Immunol. 10.1038/ni.3512. PubMed
  119. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
  120. Siegmund K, et al. 2011. J Immunol. 186:3452. PubMed
RRID
AB_312712 (BioLegend Cat. No. 100509)
AB_312713 (BioLegend Cat. No. 100510)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
Go To Top Version: 3    Revision Date: 01/29/2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account